-
The American Journal of Cardiology Nov 1983Oxprenolol is clinically a well-established beta blocker that shares with other members of this group the ability to control a variety of disorders, in particular,... (Comparative Study)
Comparative Study Review
Oxprenolol is clinically a well-established beta blocker that shares with other members of this group the ability to control a variety of disorders, in particular, hypertension and angina. Pharmacologically it is a nonselective beta blocker that possesses partial agonist activity (intrinsic sympathomimetic activity). Pharmacokinetically, oxprenolol behaves as a moderately lipophilic agent. This means that it is well absorbed, but then undergoes considerable first-pass loss. It penetrates well into most tissues, including the central nervous system. About 80% of oxprenolol is bound to protein in the blood, and when acute-phase proteins increase, as, for example, in patients with inflammatory disease, total plasma concentrations of oxprenolol also increase. Apart from this, the plasma concentration:time profile produced after the oral administration of oxprenolol is remarkably consistent and reproducible. Intrasubject and intersubject variability is small, and the administration of the drug after food or with many other drugs has very little effect. The beta-blocking effects of oxprenolol correlate well with the plasma concentrations, but as with other beta blockers, it has not been possible to correlate plasma concentrations directly with its therapeutic actions such as lowering blood pressure or controlling arrhythmias.
Topics: Adolescent; Adult; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Kinetics; Oxprenolol; Pregnancy; Time Factors; Tissue Distribution
PubMed: 6356863
DOI: 10.1016/0002-9149(83)90639-2 -
Pharmacotherapy 1983Oxprenolol is a nonselective beta-adrenergic blocking agent that also possesses intrinsic sympathomimetic activity (ISA) and membrane stabilizing effects. Oxprenolol... (Review)
Review
Oxprenolol is a nonselective beta-adrenergic blocking agent that also possesses intrinsic sympathomimetic activity (ISA) and membrane stabilizing effects. Oxprenolol undergoes first pass metabolism with only 30% of an oral dose reaching the systemic circulation. The drug is approximately 80% protein bound and is eliminated primarily by glucuronidation in the liver. Less than 4% of oxprenolol is excreted unchanged in the urine. Oxprenolol may reduce the heart rate and prolong the effective and functional atrioventricular nodal refractory period. Oxprenolol has less negative inotropic and chronotropic effects than propranolol. Plasma renin activity is reduced; however, changes in plasma aldosterone level are not significant. Long term metabolic effects require further study. Oxprenolol appears to be comparable to other beta blockers in the treatment of hypertension and angina pectoris with no additional adverse reactions. If its partial agonist effect proves useful, it may have an advantage over other agents in treating patients with borderline cardiac reserve. Because of limited data, the use of oxprenolol for the treatment of arrhythmias, migraine, thyrotoxicosis, anxiety, and glaucoma cannot be recommended at this time.
Topics: Airway Resistance; Angina Pectoris; Arrhythmias, Cardiac; Cell Membrane; Chemical Phenomena; Chemistry; Hemodynamics; Humans; Hypertension; Kinetics; Lipoproteins; Oxprenolol; Renin; Sympathomimetics
PubMed: 6344036
DOI: No ID Found -
Lancet (London, England) Jan 1973
Clinical Trial
Topics: Adult; Aged; Clinical Trials as Topic; Heart Rate; Humans; Hyperthyroidism; Middle Aged; Oxprenolol; Placebos
PubMed: 4118822
DOI: 10.1016/s0140-6736(73)90038-x -
Lancet (London, England) May 1973
Clinical Trial Randomized Controlled Trial
Topics: Anxiety; Diazepam; Humans; Oxprenolol
PubMed: 4123586
DOI: 10.1016/s0140-6736(73)91202-6 -
Medicine, Science, and the Law Oct 1977
Topics: Female; Forensic Medicine; Humans; Middle Aged; Oxprenolol; Suicide
PubMed: 927094
DOI: 10.1177/002580247701700412 -
British Medical Journal Mar 1977
Topics: Emetics; Female; Humans; Middle Aged; Oxprenolol; Sodium Chloride; Suicide
PubMed: 851756
DOI: 10.1136/bmj.1.6064.840-b -
Acta Neurologica Scandinavica Aug 1977Thirty migraine patients received oxprenolol (Trasicor), which is an adrenergic beta-receptor blocking agent with weak beta-stimulating intrinsic activity. The dosage... (Clinical Trial)
Clinical Trial
Thirty migraine patients received oxprenolol (Trasicor), which is an adrenergic beta-receptor blocking agent with weak beta-stimulating intrinsic activity. The dosage was 80 mg three times a day. The treatment was given by a double blind cross-over technique in which the effect was compared with placebo. Each compound was administered for 8 weeks with an intermediate week without medication (wash-out). Oxprenolol had no significant effects in the prevention of migraine attacks. Our study lends further support to the assumption that differences may exist between different beta-receptor blocking agents in their effectiveness in migraine prophylaxis.
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxprenolol
PubMed: 331835
DOI: 10.1111/j.1600-0404.1977.tb01423.x -
British Medical Journal Feb 1977
Topics: Female; Humans; Middle Aged; Oxprenolol
PubMed: 843802
DOI: 10.1136/bmj.1.6060.552 -
Scottish Medical Journal Nov 1975
Topics: Adrenergic beta-Antagonists; Aged; Drug Administration Schedule; Handwriting; Humans; Oxprenolol; Tremor
PubMed: 4891
DOI: 10.1177/003693307502000611 -
British Medical Journal Mar 1977
Topics: Adult; Female; Heart Arrest; Heart Massage; Humans; Oxprenolol
PubMed: 851731
DOI: 10.1136/bmj.1.6063.776-d